Format

Send to

Choose Destination
J Control Release. 2017 Sep 10;261:199-206. doi: 10.1016/j.jconrel.2017.07.002. Epub 2017 Jul 3.

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

Author information

1
Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Sweden; Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Sweden.
2
Department of Cellular & Molecular Medicine, UCSD School of Medicine, La Jolla, California, USA.
3
Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Sweden.
4
Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Sweden.
5
Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Sweden; Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Sweden. Electronic address: caroline.palm.apergi@ki.se.

Abstract

Epidemiological studies of childhood leukemia survivors reveal an alarmingly high incidence of chronic health disabilities after treatment, therefore, more specific therapies need to be developed. Polo-like kinase 1 (Plk1) is a key player in mitosis and a target for drug development as it is upregulated in multiple cancer types. Small molecules targeting Plk1 are mainly ATP-competitors and, therefore, are known to elicit side effects due to lack of specificity. RNA interference (RNAi) is known for its high catalytic activity and target selectivity; however, the biggest barrier for its introduction into clinical use is its delivery. RNAi prodrugs are modified, self-delivering short interfering Ribonucleic Neutrals (siRNNs), cleaved by cytoplasmic enzymes into short interfering Ribonucleic Acids (siRNAs) once inside cells. In this study we aimed to investigate the potential of siRNNs as therapeutic tools in T-acute lymphoblastic leukemia (T-ALL) using T-ALL cell lines and patient-derived samples. We demonstrate for the first time that RNAi prodrugs (siRNNs) targeting Plk1, can enter pediatric T-ALL patient cells without a transfection reagent and induce Plk1 knockdown on both protein and mRNA levels resulting in G2/M-arrest and apoptosis. We also show that siRNNs targeting Plk1 generate less toxicity in normal cells compared to the small molecule Plk1 inhibitor, BI6727, suggesting a potentially good therapeutic index.

KEYWORDS:

BI6727; Drug delivery; Pediatric leukemia; Polo-like kinase; RNA interference; RNAi prodrug

PMID:
28684168
DOI:
10.1016/j.jconrel.2017.07.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center